Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for breast cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Perspectives on Conversations About Costs of Cancer Care of BreastCancer Survivors and Cancer Center Staff: A Qualitative Study. Despite recommendations to discuss the cost of care (CoC) with patients with cancer, little formal guidance is available on how to conduct these sensitive conversations in ways that are acceptable to both patients and providers.To explore the perspectives of patients and medical and nonmedical cancer center staff on CoC conversations.In individual interviews (...) , participants were asked to discuss the content of, timing of, and ideal person to hold CoC conversations. Interviews were transcribed verbatim. Content was analyzed to identify emerging essential elements.Division of Preventive Medicine, University of Alabama at Birmingham.42 women aged 60 to 79 years with a history of breastcancer and 20 cancer center staff (6 physicians, 4 nurses, 5 patient navigators, 3 social workers, and 2 billing specialists).Both patients and providers identified reassurance
Risk-reducing medications for primary breastcancer: a network meta-analysis. Breastcancer is the most frequently occurring malignancy and the second cause of death for cancer in women. Cancer prevention agents (CPAs) are a promising approach to reduce the burden of breastcancer. Currently, two main types of CPAs are available: selective estrogen receptor modulators (SERMs, such as tamoxifen and raloxifene) and aromatase inhibitors (AIs, such as exemestane and anastrozole).To assess (...) the efficacy and acceptability of single CPAs for the prevention of primary breastcancer, in unaffected women, at an above-average risk of developing breast cancer.Using a network meta-analysis, to rank single CPAs, based on their efficacy and acceptability (an endpoint that is defined as the inverse of CPA-related toxicity).We searched the Cochrane BreastCancer Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, World Health Organization's International
Screening for BreastCancer in Average-Risk Women: A Guidance Statement From the American College of Physicians. The purpose of this guidance statement is to provide advice to clinicians on breastcancer screening in average-risk women based on a review of existing guidelines and the evidence they include.This guidance statement is derived from an appraisal of selected guidelines from around the world that address breastcancer screening, as well as their included evidence. All national (...) is all clinicians, and the target patient population is all asymptomatic women with average risk for breast cancer.In average-risk women aged 40 to 49 years, clinicians should discuss whether to screen for breastcancer with mammography before age 50 years. Discussion should include the potential benefits and harms and a woman's preferences. The potential harms outweigh the benefits in most women aged 40 to 49 years.In average-risk women aged 50 to 74 years, clinicians should offer screening
Stage I BreastCancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women American College of Radiology End User License Agreement ACR Appropriateness Criteria is a registered trademark of the American College of Radiology. By accessing the ACR Appropriateness Criteria®, you expressly agree and consent to the terms and conditions as described at: http://www.acr.org/~/media/ACR/Documents/AppCriteria/TermsandConditions.pdf Personal use of material (...) Cancer American College of Radiology ACR Appropriateness Criteria ® Clinical Condition: Stage I BreastCancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women Variant 1: Newly diagnosed. Initial workup. Rule out bone metastases. Radiologic Procedure Rating Comments RRL* FDG-PET/CT whole body 2 ???? Tc-99m bone scan whole body 1 ??? X-ray skeletal survey 1 ??? Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually
Accuracy of Self-Report for Cervical and BreastCancer Screening Management Briefs eBrief-no152 -- Accuracy of Self-Report for Cervical and BreastCancer Screening Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no152 -- Accuracy of Self-Report for Cervical and BreastCancer Screening Health Services Research & Development Management eBrief no. 152 » Issue 152 April 2019 (...) The report is a product of the VA/HSR&D Evidence Synthesis Program. Evidence Brief: Accuracy of Self-Report for Cervical and BreastCancer Screening Guideline-based breast and cervical cancer screening are considered essential health benefits and are fundamental components of high-quality primary care services in the United States. The aim of cancer screening is to identify cancers in an early stage when treatment is more likely to be effective. Accurate measurement of cancer screening rates is vital
Mindfulness-based stress reduction for women diagnosed with breastcancer. Breastcancer is the most common cancer in women. Diagnosis and treatment may drastically affect quality of life, causing symptoms such as sleep disorders, depression and anxiety. Mindfulness-based stress reduction (MBSR) is a programme that aims to reduce stress by developing mindfulness, meaning a non-judgmental, accepting moment-by-moment awareness. MBSR seems to benefit patients with mood disorders and chronic pain (...) , and it may also benefit women with breast cancer.To assess the effects of mindfulness-based stress reduction (MBSR) in women diagnosed with breast cancer.In April 2018, we conducted a comprehensive electronic search for studies of MBSR in women with breastcancer, in the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and two trial registries (World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP) and ClinicalTrials.gov). We also handsearched
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative BreastCancer. Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breastcancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker (...) for metastatic triple-negative breastcancer. The end points included safety; the objective response rate (according to Response Evaluation Criteria in Solid Tumors, version 1.1), which was assessed locally; the duration of response; the clinical benefit rate (defined as a complete or partial response or stable disease for at least 6 months); progression-free survival; and overall survival. Post hoc analyses determined the response rate and duration, which were assessed by blinded independent central
Surgical interventions for the prevention or treatment of lymphoedema after breastcancer treatment. Breastcancer is the most common type of cancer amongst women worldwide, and one distressing complication of breastcancer treatment is breast and upper-limb lymphoedema. There is uncertainty regarding the effectiveness of surgical interventions in both the prevention and management of lymphoedema affecting the arm after breastcancer treatment.1. To assess and compare the efficacy of surgical (...) interventions for the prevention of the development of lymphoedema (LE) in the arm after breastcancer treatment.2. To assess and compare the efficacy of surgical interventions for the treatment of established LE in the arm after breastcancer treatment.We searched the Cochrane BreastCancer Group's Specialised Register, the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the WHO International Clinical Trials Registry
Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breastcancer. Anthracyclines and taxanes are chemotherapeutic agents widely used in a sequential regimen in the adjuvant and neoadjuvant treatment of early breastcancer to reduce the risk of cancer recurrence. Standard practice is to administer anthracycline-based chemotherapy followed by a taxane. Anthracyclines tend to be administered first as they were established before taxanes for treatment of early (...) breast cancer.To assess whether the sequence in which anthracyclines and taxanes are administered affects outcomes for people with early breastcancer receiving adjuvant or neoadjuvant therapy.We searched Cochrane BreastCancer's Specialised Register, CENTRAL, MEDLINE, Embase, the World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP) and ClinicalTrials.gov on 1 February 2018.Randomised controlled trials comparing administering a taxane prior to an anthracycline
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breastcancer in 26 randomised trials. Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles, or by giving individual drugs sequentially at full dose rather than in lower-dose concurrent treatment schedules, might enhance efficacy.To clarify the relative benefits and risks of dose-intense (...) and standard-schedule chemotherapy in early breastcancer, we did an individual patient-level meta-analysis of trials comparing 2-weekly versus standard 3-weekly schedules, and of trials comparing sequential versus concurrent administration of anthracycline and taxane chemotherapy. The primary outcomes were recurrence and breastcancer mortality. Standard intention-to-treat log-rank analyses, stratified by age, nodal status, and trial, yielded dose-intense versus standard-schedule first-event rate ratios
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breastcancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial The optimal duration of extended therapy with aromatase inhibitors in patients with postmenopausal breastcancer is unknown. In the NSABP B-42 study, we aimed to determine whether extended letrozole treatment improves disease-free survival after 5 years of aromatase inhibitor-based therapy in women with postmenopausal (...) breast cancer.This randomised, double-blind, placebo-controlled, phase 3 trial was done in 158 centres in the USA, Canada, and Ireland. Postmenopausal women with stage I-IIIA hormone receptor-positive breastcancer, who were disease-free after about 5 years of treatment with an aromatase inhibitor or tamoxifen followed by an aromatase inhibitor, were randomly assigned (1:1) to receive 5 years of letrozole (2·5 mg orally per day) or placebo. Randomisation was stratified by pathological node status
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early BreastCancer: PALLET Trial CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic breastcancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of combination palbociclib plus letrozole as neoadjuvant therapy.Postmenopausal women with ER-positive primary BC and tumors greater
Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive BreastCancer: A Randomized Phase II Trial To evaluate endocrine activity in terms of ovarian function suppression (OFS) of degarelix (a gonadotropin-releasing hormone [GnRH] antagonist) versus triptorelin (a GnRH agonist) in premenopausal patients receiving letrozole as neoadjuvant endocrine therapy for breast cancer.Premenopausal women with stage cT2 to 4b, any N (...) , M0; estrogen receptor and progesterone receptor greater than 50%; human epidermal growth factor receptor 2-negative breastcancer were randomly assigned to triptorelin 3.75 mg administered intramuscularly on day 1 of every cycle or degarelix 240 mg administered subcutaneously (SC) on day 1 of cycle 1 then 80 mg SC on day 1 of cycles 2 through 6, both with letrozole 2.5 mg/day for six 28-day cycles. Surgery was performed 2 to 3 weeks after the last injection. Serum was collected at baseline, after
Common osteoporosis drugs may prevent breastcancer spreading to bone Common osteoporosis drugs may prevent breastcancer spreading to bone Discover Portal Discover Portal Common osteoporosis drugs may prevent breastcancer spreading to bone Published on 13 March 2018 doi: Drugs commonly prescribed to prevent bone thinning probably help prevent the spread of early breastcancer to the bones in a few women, when taken in addition to standard cancer therapies. However, the overall benefits may (...) be small, for example preventing spread to bone or death in about one extra woman in every 100 treated for about five years. This is a complex area because many of the treatments for breastcancer are known to worsen bone thinning, but there are other bone strengthening benefits to these drugs. This large review of 44 studies with more than 37,000 participants looked at women with either early breastcancer or advanced breastcancer with or without bone involvement. The reviewers also concluded
Delaying chemotherapy after breastcancer surgery may reduce survival chances Delaying chemotherapy after breastcancer surgery may reduce survival chances Discover Portal Discover Portal Delaying chemotherapy after breastcancer surgery may reduce survival chances Published on 31 January 2017 doi: Delaying chemotherapy after breastcancer surgery may slightly decrease a woman’s chances of survival. A review found about a 5% increase in the relative risk of death. Many women are offered (...) chemotherapy soon after breastcancer surgery, called adjuvant chemotherapy. Chemotherapy is usually started after the surgical wounds have healed but the effect of any delay to this was unclear. These researchers calculated the risk from outcomes for almost 30,000 women treated with adjuvant chemotherapy, from studies in Europe and North America. The absolute risk of death for any woman will depend on her individual cancer stage and characteristics. A four week delay could add several percentage points
BreastCancer Treatment: A Review. Breastcancer will be diagnosed in 12% of women in the United States over the course of their lifetimes and more than 250 000 new cases of breastcancer were diagnosed in the United States in 2017. This review focuses on current approaches and evolving strategies for local and systemic therapy of breast cancer.Breast cancer is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors (...) and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). More than 90% of breastcancers are not metastatic at the time of diagnosis. For people presenting without metastatic disease, therapeutic goals are tumor eradication and preventing recurrence. Triple-negative breastcancer is more likely to recur than the other 2 subtypes, with 85% 5